Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | XIAP | P98170 | 1/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.53 |
| ▸ | KIF11 | P52732 | 15/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1039559 | 1.00 | ALPI (0.53) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL13524317 | 1.00 | ALPI (0.53) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL10088140 | 0.87 | SLC7A5 (0.56) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL28751573 | 0.84 | KIF11 (0.52) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL28751572 | 0.84 | KIF11 (0.52) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL9218151 | 0.81 | ALPI (0.55) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL419615 | 0.80 | SMN1; SMN2 (0.59) | SMN1; SMN2HIF1A | |
| SCHEMBL1835145 | 0.78 | ALPI (0.55) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL1835148 | 0.78 | ALPI (0.55) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL4398300 | 0.78 | ALPI (0.55) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669080-B2 | Mutated D-aminotransferase and method for producing optically active glutamic acid derivatives using the same | AJINOMOTO CO., INC. (JP) | 2014-03-11 | — | — | US | disclosed |
| US-8563278-B2 | Process of producing glutamate derivatives | AJINOMOTO CO., INC. (JP) | 2013-10-22 | — | — | US | disclosed |
| EP-1580268-B1 | MUTANT D-AMINOTRANSFERASE AND PROCESS FOR PRODUCING OPTICALLY ACTIVE GLUTAMIC ACID DERIVATIVE USING THE SAME | AJINOMOTO KK (JP) | 2013-10-02 | — | — | EP | disclosed |
| US-8535920-B2 | Such as monatin by exposing typtophan to enzyme which converts tryptophan to 3-indolepyruvic acid which is exposed to enzyme and oxaloacetic/pyruvic acid to form 4-(indol-3-ylmethyl)-4-hydroxy-2-oxoglutaric acid | AJINOMOTO CO., INC. (JP) | 2013-09-17 | — | — | US | disclosed |
| CN-101450907-B | Processes for the preparation of glutamic acid compounds intermediates and novel intermediates used in the processes | AJINOMOTO KK | 2013-07-17 | — | — | CN | disclosed |
| EP-2557160-A2 | Mutated D-aminotransferase and method for producing optically active glutamic acid derivatives using the same | Ajinomoto Co., Inc. (JP) | 2013-02-13 | — | — | EP | disclosed |
| US-8202711-B2 | Process for producing glutamate derivatives | AJINOMOTO CO., INC. (JP) | 2012-06-19 | — | — | US | disclosed |
| EP-2460884-A2 | Process for preparing monatin | Ajinomoto Co., Inc. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120035373-A1 | PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES | AJINOMOTO CO. INC (JP) | 2012-02-09 | — | — | US | disclosed |
| US-8058034-B2 | Mutated D-aminotransferase and method for producing optically active glutamic acid derivatives using the same | AJINOMOTO CO., INC. (JP) | 2011-11-15 | — | — | US | disclosed |
| US-7064219-B2 | Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes | AJINOMOTO CO., INC. (JP) | 2006-06-20 | — | — | US | disclosed |
| US-20060074249-A1 | Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes | AJINOMOTO CO. INC (JP) | 2006-04-06 | — | — | US | disclosed |
| CN-1756734-A | Process for producing glutamic acid derivative and pyroglutamic acid derivative, and novel intermediate for production | AJINOMOTO KK (JP) | 2006-04-05 | — | — | CN | disclosed |
| US-20060003411-A1 | Mutated D-aminotransferase and method for producing optically active glutamic acid derivatives using the same | AJINOMOTO CO., INC. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1580268-A1 | MUTANT D-AMINOTRANSFERASE AND PROCESS FOR PRODUCING OPTICALLY ACTIVE GLUTAMIC ACID DERIVATIVE USING THE SAME | Ajinomoto Co., Inc. (JP) | 2005-09-28 | — | — | EP | disclosed |
| CN-1610658-A | Process for producing glutamic acid compound and intermediate for producing the same, and novel intermediate for use therein | AJINOMOTO KK (JP) | 2005-04-27 | — | — | CN | disclosed |
| US-20050009153-A1 | Such as 3-indolepyruvic acid by exposing tryptophan to amino acid oxidase/catalase, adjusting pH with sulfuric acid, then deaerating/deoxygenating | AJINOMOTO CO., INC. (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20050004394-A1 | Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes | AJINOMOTO CO. IN (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1466890-A1 | PROCESSES FOR THE PREPARATION OF GLUTAMIC ACID COMPOUNDS AND INTERMEDIATES THEREOF AND NOVEL INTERMEDIATES USED IN THE PROCESSES | Ajinomoto Co., Inc. (JP) | 2004-10-13 | — | — | EP | disclosed |
| EP-1445323-A1 | PROCESS FOR PRODUCTION OF GLUTAMIC ACID DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2004-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003411-A1 | Mutated D-aminotransferase and method for producing optically active glutamic acid derivatives using the same | GOT1, AADAT, GOT2 | ALPI 136/4885PKM 2460/4885PTGS1 3746/4885 |
| US-20120035373-A1 | PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES | GLUL, MON2, GRIK5 | ALPI 3083/4885PKM 798/4885PTGS1 2753/4885 |
| US-20050004394-A1 | Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes | GLUL, MON2, GRIK5 | ALPI 3083/4885PKM 798/4885PTGS1 2753/4885 |
| US-20060074249-A1 | Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes | GLUL, MON2, GRIK5 | ALPI 3083/4885PKM 798/4885PTGS1 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.